Erythropoietic effects of prostacyclin (PGI2) and its metabolite 6-keto-prostaglandin (PG)E1.
D015064:16,16-Dimethylprostaglandin E2 / Q000494:pharmacology; D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D001101:Arbaprostil / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology*; D004920:Erythropoiesis / Q000187:drug effects*; D005260:Female; D007501:Iron / Q000378:metabolism; D051379:Mice; D011086:Polycythemia / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology*
D011453:Prostaglandins; D011458:Prostaglandins E; C022950:6-ketoprostaglandin E1; D011464:Epoprostenol; D007501:Iron; D011451:Prostaglandin-Endoperoxide Synthases; D000527:Alprostadil; D001101:Arbaprostil; D015064:16,16-Dimethylprostaglandin E2